Ionis Pharmaceuticals Management
Management criteria checks 2/4
Ionis Pharmaceuticals' CEO is Brett Monia, appointed in Jan 2020, has a tenure of 4.25 years. total yearly compensation is $12.50M, comprised of 7.7% salary and 92.3% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth €6.86M. The average tenure of the management team and the board of directors is 4.3 years and 7.9 years respectively.
Key information
Brett Monia
Chief executive officer
US$12.5m
Total compensation
CEO salary percentage | 7.7% |
CEO tenure | 4.3yrs |
CEO ownership | 0.1% |
Management average tenure | 4.3yrs |
Board average tenure | 7.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$13m | US$961k | -US$366m |
Sep 30 2023 | n/a | n/a | -US$409m |
Jun 30 2023 | n/a | n/a | -US$309m |
Mar 31 2023 | n/a | n/a | -US$329m |
Dec 31 2022 | US$7m | US$825k | -US$270m |
Sep 30 2022 | n/a | n/a | US$7m |
Jun 30 2022 | n/a | n/a | -US$28m |
Mar 31 2022 | n/a | n/a | -US$4m |
Dec 31 2021 | US$13m | US$800k | -US$29m |
Sep 30 2021 | n/a | n/a | -US$608m |
Jun 30 2021 | n/a | n/a | -US$550m |
Mar 31 2021 | n/a | n/a | -US$495m |
Dec 31 2020 | US$11m | US$700k | -US$444m |
Sep 30 2020 | n/a | n/a | US$94m |
Jun 30 2020 | n/a | n/a | US$145m |
Mar 31 2020 | n/a | n/a | US$169m |
Dec 31 2019 | US$7m | US$528k | US$281m |
Sep 30 2019 | n/a | n/a | US$433m |
Jun 30 2019 | n/a | n/a | US$402m |
Mar 31 2019 | n/a | n/a | US$366m |
Dec 31 2018 | US$4m | US$508k | US$277m |
Sep 30 2018 | n/a | n/a | -US$41m |
Jun 30 2018 | n/a | n/a | -US$38m |
Mar 31 2018 | n/a | n/a | US$9m |
Dec 31 2017 | US$2m | US$443k | US$19m |
Compensation vs Market: Brett's total compensation ($USD12.50M) is above average for companies of similar size in the German market ($USD3.35M).
Compensation vs Earnings: Brett's compensation has increased whilst the company is unprofitable.
CEO
Brett Monia (62 yo)
4.3yrs
Tenure
US$12,500,023
Compensation
Dr. Brett P. Monia, Ph.D. is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been Chief Executive Officer since January 2020. He has extensive experience across a range of therapeutic areas, inclu...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 4.3yrs | US$12.50m | 0.12% $ 6.9m | |
Executive VP of Finance & CFO | 11.3yrs | US$2.89m | 0.064% $ 3.7m | |
Director | 6.3yrs | US$538.04k | 0.057% $ 3.2m | |
Executive VP & Chief Development Officer | 15.7yrs | US$2.56m | 0.060% $ 3.5m | |
Executive Vice President of Research | 4.3yrs | US$2.56m | 0.024% $ 1.4m | |
Chief Accounting Officer & Senior VP | 4.2yrs | no data | no data | |
Executive VP & Chief Scientific Officer | 4.3yrs | US$958.87k | 0.054% $ 3.1m | |
Senior Vice President of Investor Relations | no data | no data | no data | |
Executive VP | 11.3yrs | US$3.92m | 0.033% $ 1.9m | |
Vice President of Corporate Communications | less than a year | no data | no data | |
Senior Vice President of Human Resources | 4.2yrs | no data | no data | |
Scientific Advisor | 2.8yrs | US$2.28m | no data |
4.3yrs
Average Tenure
63.5yo
Average Age
Experienced Management: ISI's management team is considered experienced (4.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 5.1yrs | US$12.50m | 0.12% $ 6.9m | |
Director | 23.6yrs | US$538.04k | 0.057% $ 3.2m | |
Independent Director | 4.8yrs | US$540.04k | 0.026% $ 1.5m | |
Independent Director | 18.3yrs | US$542.04k | 0.015% $ 882.9k | |
Lead Independent Director | 30.3yrs | US$598.04k | 0.077% $ 4.4m | |
Independent Director | 5.6yrs | US$528.04k | 0.022% $ 1.3m | |
Independent Director | 21.9yrs | US$548.04k | 0.10% $ 5.8m | |
Independent Chairman of the Board | 10.2yrs | US$568.04k | 0.028% $ 1.6m | |
Independent Director | 2.8yrs | US$530.04k | 0.0087% $ 498.5k | |
Independent Director | less than a year | US$363.05k | no data |
7.9yrs
Average Tenure
69yo
Average Age
Experienced Board: ISI's board of directors are considered experienced (7.9 years average tenure).